11 Spam-Free Article(s) Found
Sort:
Relevance
Like
Date
Filter:
7d
All
DeepLinks
Article Searches
Inhibrx (INBX) Up 6% on Sale of Rare Disease Drug to Sanofi https://www.zacks.com/stock/news/2214518/inhibrx-inbx-up-6-on-sale-of-rare-disease-drug-to-sanofi?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2214518 Jan 23, 2024 - Sanofi (SNY) will acquire Inhibrx (INBX) for nearly $2.2 billion. Post-acquisition, it will retain the rare disease drug and spin out all other pipeline programs into a newly-traded public company.
Pharma Stock Roundup: PFE, MRK, NVO & SNY's Q4 Earnings, FDA Updates https://www.zacks.com/stock/news/2220214/pharma-stock-roundup-pfe-mrk-nvo-sny-s-q4-earnings-fda-updates?cid=CS-ZC-FT-analyst_blog|stock_roundup-2220214 Feb 02, 2024 - Pfizer (PFE), Merck (MRK), Novartis (NVS), Novo Nordisk (NVO) and Sanofi (SNY) announce fourth-quarter and full-year 2023 results.
Top Analyst Reports for Microsoft, Amazon.com & Berkshire Hathaway https://www.zacks.com/commentary/2230125/top-analyst-reports-for-microsoft-amazon-com-berkshire-hathaway?cid=CS-ZC-FT-research_daily-2230125 Feb 22, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Amazon.com, Inc. (AMZN) and Berkshire Hathaway Inc. (BRK.B).
Regeneron (REGN) Gets FDA Nod for Praluent Label Extension https://www.zacks.com/stock/news/2239502/regeneron-regn-gets-fda-nod-for-praluent-label-extension?cid=CS-ZC-FT-analyst_blog|earnings_article-2239502 Mar 12, 2024 - Regeneron (REGN) obtains FDA approval for Praluent as an adjunct to diet and other LDL-C, lowering therapies to include pediatric patients aged eight and older with HeFH.
Biotech Stock Roundup: GILD Down on Study Results, INBX Gains on Sanofi Deal & More https://www.zacks.com/stock/news/2215085/biotech-stock-roundup-gild-down-on-study-results-inbx-gains-on-sanofi-deal-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2215085 Jan 24, 2024 - Gilead Sciences (GILD) and Inhibrx (INBX) are in the spotlight on regulatory and pipeline updates.
Why Sanofi (SNY) Might Surprise This Earnings Season https://www.zacks.com/stock/news/2218829/why-sanofi-sny-might-surprise-this-earnings-season?cid=CS-ZC-FT-tale_of_the_tape|earnings_surprise-2218829 Jan 31, 2024 - Sanofi (SNY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Sanofi (SNY) Misses on Q4 Earnings and Sales, Stock Down https://www.zacks.com/stock/news/2219619/sanofi-sny-misses-on-q4-earnings-and-sales-stock-down?cid=CS-ZC-FT-analyst_blog|earnings_article-2219619 Feb 01, 2024 - Sanofi (SNY) misses fourth-quarter estimates for earnings and sales. It maintains 2024 earnings growth guidance.
TEVA Q4 Earnings and Revenues Surpass Estimates, Stock Up https://www.zacks.com/stock/news/2219707/teva-q4-earnings-and-revenues-surpass-estimates-stock-up?cid=CS-ZC-FT-analyst_blog|earnings_article-2219707 Feb 01, 2024 - TEVA reports better-than-expected fourth-quarter results, beating both earnings and sales estimates. The stock gains 3% in response.
Sanofi (SNY) Q4 2023 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2024/02/01/sanofi-sny-q4-2023-earnings-call-transcript/?source=iedfolrf0000001 Feb 01, 2024 - SNY earnings call for the period ending December 31, 2023.
ASLAN (ASLN) Up 161% on Upbeat Initial Data From Eczema Study https://www.zacks.com/stock/news/2239307/aslan-asln-up-161-on-upbeat-initial-data-from-eczema-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2239307 Mar 12, 2024 - ASLAN (ASLN) rises on upbeat initial data from a phase II study of eblasakimab in patients with eczema, who have previously been treated with Dupixent but did not achieve an adequate response.

Pages: 12

Page 1